Preservation of vision in patients with diabetes mellitus is critical. Interventions to improve glycemic control through early intensive treatment of diabetes reduce rates of severe retinopathy and preserve visual acuity. 
T he National Eye Institute Visual Function Questionnaire (NEI-VFQ) has been used to assess the relationship of diabetic retinopathy severity and visual acuity (VA) with patient-reported visual function. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] Data from previous studies have shown that severe retinopathy and poorer VA adversely affect self-report of visual function and that interventions that improve VA, such as vitrectomy and laser photocoagulation, have a beneficial effect as measured by the NEI-VFQ. To our knowledge, the long-term effect of intensive glycemic control on the patient-reported visual function in a controlled clinical trial in type 1 diabetes mellitus has not been examined. In the Diabetes Control and Complications Trial (DCCT), intensive insulin treatment of type 1 diabetes reduced the risk of development and progression of diabetic retinopathy compared with conventional diabetes treatment. The salutary effects of intensive vs conventional treatment were maintained during the Epidemiology of Diabetes Interventions and Complications (EDIC) observational follow-up of the DCCT cohort. 13, 14 The purpose of this study is to assess the longterm effects of prior intensive treatment and risk factors on patient-reported visual function, using the 25-item NEI-VFQ (NEI-VFQ-25), 30 years after the start of the DCCT.
Methods
The DCCT/EDIC has been described in detail in previous reports. 15,16 Between 1983 and 1989 , 1441 participants with type 1 diabetes, aged 13 to 39 years, provided written informed consent and were enrolled in the DCCT, an institutional review board-approved multicenter clinical trial comparing the effects of intensive treatment, aimed at lowering glycemia as close to the nondiabetic range as safely possible, with those of conventional treatment. Intensive treatment, which aimed for hemoglobin A 1c (HbA 1c ) levels lower than 6.05% of total hemoglobin (to convert to proportion of total hemoglobin, multiply by 0.01), used 3 or more daily insulin injections or treatment with insulin pumps, with dose selection guided by frequent self-monitoring of blood glucose level. Conventional treatment had no numeric blood glucose targets but aimed for the absence of symptoms of hyperglycemia and hypoglycemia with 1 or 2 daily injections of insulin, the standard therapy at the time. The trial included 2 cohorts. The primary prevention cohort had diabetes for 1 to 5 years, an albumin excretion rate (AER) less than 40 mg/24 hours, and no retinopathy. The secondary intervention cohort had diabetes for 1 to 15 years, very mild to moderate nonproliferative retinopathy, and an AER equal to or lower than 200 mg/24 hours. After study end, the conventionally treated participants were instructed in intensive treatment and all patients were encouraged to implement and instructed in the use of intensive treatment. All participants were then referred to their health care professionals for ongoing diabetes care. 
Patient-Reported Visual Function Outcomes
Beginning in 2004, EDIC administered the NEI-VFQ-25 among one-quarter of the cohort every year. The NEI-VFQ-25 consists of a base set of 25 vision-targeted questions representing 11 vision-related domains including general vision, ocular pain, near vision, distance vision, limitation on social functioning, mental health symptoms due to vision, role difficulties, dependency on others, driving difficulty, limitation with color vision, and limitation with peripheral vision, plus an additional single-item general health domain question. Subscale scores ranging from 0 to 100 (with 100 indicating highest function) were generated for each of the 12 domains. The main outcome in our analysis is the composite NEI-VFQ-25 score, which is an average of the 11 vision-related subscale scores. A composite quality-of-life (QOL) score was also examined, which comprises all of the 12 subscales including general health.
Visual Acuity
Measurement of VA was performed by certified EDIC VA examiners every 4 years in EDIC based on the Early Treatment Diabetic Retinopathy Study (ETDRS) charts and procedures. The VA was determined for each eye individually and tested first at the 4-m distance. If the number of letters read correctly at 4 m was less than 20, the test was repeated at 1 m. If the number of letters read correctly at 1 m was 0, then the patient's ability to count fingers, detect hand motion, or have light perception was evaluated. For each eye, the best-corrected VA was recorded as the number of letters read correctly from 0 through 2 (worse than 20/800) to 98 through 100 (20/10) . For each participant, the better eye was based on comparison of the best-corrected VA of each eye tested. 17 
Retinopathy and Ocular Surgery
During EDIC, retinopathy was assessed by standardized 7-field fundus photography in one-quarter of the cohort each year and in the entire cohort at EDIC years 4 and 10. All photographs were Clinically significant macular edema was based on the detailed grading of fundus photographs and was defined as the presence of any 1 of the following: retinal thickening at or within 500 μm of the center of the macula; hard exudates at or within 500 μm of the center of the macula if associated with thickening of the adjacent retina; or a zone or zones of retinal thickening 1 disc area in size, at least part of which was within 1 disc diameter of the center. 19 Panretinal and focal photocoagulation was assessed by patient annual report and confirmed by grading of photocoagulation scars in fundus photographs. Ocular surgery, including cataract extraction, vitrectomy, glaucoma-related surgery, corneal-related surgery, capsulotomy, and eye enucleation, were reported annually in DCCT and EDIC.
Biomedical and Clinical Evaluations
Demographic characteristics, marital status, education, unemployment status, and history of smoking were assessed by annual questionnaires. Blood pressure and HbA 1c level were measured quarterly during DCCT and annually during EDIC. 20 The AER and plasma lipid concentrations were measured yearly during DCCT and every 2 years during EDIC.
21 The serum creatinine level was measured annually in DCCT and EDIC. The estimated glomerular filtration rate (eGFR) was calculated from serum creatinine level, age, sex, and race using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 22 Nephropathy outcomes reported in the current analysis are a single or sustained eGFR lower than 60 mL/min/1.73 m 2 , an AER greater than 300 mg/24 hours, or a sustained AER greater than 30 mg/24 hours on 2 consecutive visits. 22 Clinical neurologic assessment, nerve conduction study, and cardiac autonomic neuropathy testing were conducted at EDIC years 13 and 14. 23, 24 Cardiac autonomic neuropathy testing was repeated at EDIC years 16 and 17. Confirmed clinical neuropathy was defined as the presence of definite clinical neuropathy (the presence of signs and symptoms consistent with distal symmetrical polyneuropathy based on examination by a board-certified neurologist) and confirmed by abnormal nerve conduction (≥1 abnormal attribute in ≥2 anatomically distinct nerves among the sural, peroneal, or median nerves). 24 Cardiac autonomic neuropathy was defined as either an R-R variation less than 15 or an R-R variation between 15 and 19.9 in combination with a Valsalva ratio of 1.5 or lower or a decrease of more than 10 mm Hg in diastolic blood pressure on postural testing.
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Diabetes-Related QOL
The diabetes-related QOL (DQOL) questionnaire was administered annually in DCCT and at every other year during EDIC. The DQOL questionnaire is a self-administered, multiplechoice, 46-item questionnaire assessing different aspects of QOL including satisfaction, impact, diabetes worry, and social or vocational worry.
25
Psychiatric Events
Psychiatric history was reported annually during EDIC. Presence of a psychiatric event was defined as at least 1 occurrence of nervousness or anxiety, affective disorder, or suicide attempt, with inpatient or outpatient treatment for the event during the year in which it was reported.
Statistical Analysis
Clinical characteristics were compared using Wilcoxon rank sum test for quantitative or ordinal variables and χ 2 test for categorical variables. The composite NEI-VFQ-25 score or QOL scale score used in the analyses was a weighted average of the subscales with an equal weight assigned to each of the 11 (excluding general health) or 12 (including general health) subscales rather than to each of the 25 questions. Internal consistency reliability among the NEI-VFQ-25 subscales was assessed with Cronbach α. 26 Spearman correlation was used to evaluate the strength of the association among the NEI-VFQ-25 subscales and of the NEI-VFQ-25 with each risk factor. Between-group comparisons in composite and subscale scores were conducted by Wilcoxon rank sum test. For subscale comparisons, to adjust for multiple tests, the Benjamini and Hochberg method was used to control the false discovery rate at the .05 level. 27 Owing to the ordinal scoring and a skewed distribution of the NEI-VFQ-25 scores, quantile regression was used to assess the effect of former DCCT treatment groups and risk factors on median NEI-VFQ-25 composite score. 28, 29 Robust confidence intervals and P values were generated with Huber sandwich estimates to incorporate any data that were not identically or independently distributed. 30 The proportion of the treatment group effect explained by each covariate was calculated as the percentage of reduction in the magnitude of the t value for the treatment group effect before and after adjustment for the covariate. All analyses were performed using SAS version 9.3 statistical software (SAS Institute, Inc).
Results
Clinical Characteristics
The characteristics of the 1184 DCCT/EDIC participants (at the time of survey completion: mean [SD] age, 52.3 [6.9] years; 48% female) who completed the NEI-VFQ-25 in EDIC years 17 through 20 are described in Table 1 , by original DCCT treatment group (intensive treatment, n = 605; conventional treatment, n = 579). At DCCT entry, there was a marginally significant difference between treatment groups in age. During the DCCT and by study design, the intensive treatment group had a significantly lower mean HbA 1c level than the conventional treatment group (7.2% vs 9.0% of total hemoglobin, respectively; P < .001). During EDIC, the mean HbA 1c for both the intensive and conventional treatment groups converged (approximately 8.0% of total hemoglobin for both groups; P = .59).
The overall DCCT/EDIC updated mean HbA 1c level remained statistically lower in the intensive treatment group (7.8% vs 8.2% of total hemoglobin, respectively; P < .001).
By EDIC years 17 through 20, the original DCCT intensive treatment group, as compared with the conventional treatment group, had significantly less overall retinopathy severity (P < .001), a lower prevalence of clinically significant macular edema (16.4% vs 25.2%, respectively; P < .001), better VA in the better eye (P = .049) and worse eye (P = .048), and a decreased incidence of ocular surgery (8.6% vs 14.9%, respectively; P < .001). 31 The intensive treatment group also demonstrated a significantly lower incidence of renal complications in DCCT/EDIC including an AER greater than 300 mg/24 hours or sustained eGFR less than 60 mL/min/1.73 m 2 (8.4% vs 16.6%, respectively; P < .001) and sustained AER greater than 30 mg/24 hours or single eGFR less than 60 mL/min/1.73 m 2 (27.3% vs 36.8%, respectively; P < .001), as well as a significantly lower prevalence of confirmed clinical neuropathy (23.6% vs 32.8%, respectively; P < .001). Notably, after 30 years, the DQOL and the number of psychiatric events were similar between the 2 treatment groups. 
Effect of Intensive Diabetes Management on Patient-Reported Visual Function
The distributions of scores on the NEI-VFQ-25 and its subscales are presented in Table 2 . The overall NEI-VFQ-25 score in both treatment groups was high (all participants: median, 91.7; interquartile range, 89.7-96.9; intensive treatment: median, 94.7; interquartile range, 91.0-97.2; conventional treatment: median, 94.0; interquartile range, 88.4-96.9; P = .006 for intensive vs conventional). Few participants had scale scores at or near 0, while a sizable proportion had scale scores of 100. Subscale scores for general health and general vision were lowest (ie, median score ≤80). The intensive treatment group had significantly higher subscale scores in the visual health domains of difficulty with distance activities (P = .001), mental health symptoms due to vision (P < .001), and driving difficulty (P < .001). Multivariate analyses of treatment group effect on patient-reported visual function (not including general health) after adjustment for age, sex, HbA 1c level at DCCT screening, and retinopathy level at DCCT baseline demonstrated a modest, yet statistically significant, lower NEI-VFQ-25 score in the conventional treatment group compared with the intensive treatment group (median difference, −1.0; 95% CI, −1.7 to −0.3; P = .006) ( Table 3) . These differences, while statistically significant, were not in the range usually considered clinically meaningful. [32] [33] [34] [35] The treatment group effect on patient-reported visual function was largely attributed to the higher DCCT mean HbA 1c level and more rapid progression of retinopathy in the conventional treatment group (explained treatment group effect, 100% and 79%, respectively) (Figure) .
All multi-item subscales demonstrated a moderately high internal consistency (Cronbach α = .62-.87) (eTable 2 in the Supplement), similar to those reported in other studies. 1, 7, 8 The Spearman correlation among the 11 visual-related subscales ranges from 0.13 (between general health and limitation with Abbreviations: IQR, interquartile range; QOL, quality of life. a P values are from between-group comparisons using Wilcoxon rank sum test. For subscale comparisons, the Benjamini and Hochberg false discovery rate α adjustment for multiple tests was also conducted to control the overall false discovery rate at the .05 level.
b Remained significant after Benjamini and Hochberg false discovery rate α adjustment (difficulty with distance activities, P = .002; mental health symptoms due to vision, P = .006; and difficulty driving, P = .001). c Lost significance after Benjamini and Hochberg false discovery rate α adjustment (P > .05). 
Risk Factors Affecting NEI-VFQ-25 Scores
Among participants in both treatment groups combined, univariate analysis revealed that the overall NEI-VFQ-25 score was most strongly associated with the following risk factors ( 004; all others, P < .001). Particularly, those with VA worse than 20/100 reported the lowest NEI-VFQ-25 score, further supporting the validity of the measure. The NEI-VFQ-25 score decreased to a median of 81 when VA was poorer than 20/100 in the worse eye and further declined to 49 if the better eye was similarly impaired. In multivariate risk factor analyses (Table 4) , sex, depression or psychiatric events in EDIC, clinically significant macular edema, reduced VA, prior ocular surgery, and higher mean HbA 1c level in DCCT/EDIC were associated with significantly lower patient-reported visual function, when adjusted for all other risk factors (P < .05). Those with VA poorer than 20/100 in the worse eye had a 21-point lower median NEI-VFQ-25 score (95% CI, −40.5 to −1.6; P = .03) compared with those with VA 20/20 or better.
Discussion
The NEI-VFQ-25 has been shown to be a reliable and valid questionnaire for patients with 5 chronic eye conditions or low vision from any cause. 36 The data presented herein extend these findings to the DCCT/EDIC cohort of persons with long-term type 1 diabetes. Remarkably, after an average duration of diabetes of 30 years, the overall NEI-VFQ-25 score among all questionnaire participants is very high, with a median composite score of 91.7 at EDIC years 17 through 20, almost certainly reflecting the modest degree of eye disease in the DCCT/EDIC cohort. Notably, although both former treatment groups reported relatively high NEI-VFQ-25 scores, intensive management of diabetes during the DCCT still resulted in a statistically significant higher NEI-VFQ-25 composite score, up to 30 years after the start of the DCCT. To our knowledge, this is the first report of a difference (albeit only approximately 1.0 point on average on a median score of approximately 92) (Table 3) in NEI-VFQ-25 scores (not including general health) in conventional compared with intensive diabetes management. Despite differences in incidence of ocular and systemic complications between the intensive and conventional treatment groups, the difference in the scores for the NEI-VFQ-25, 1.0, is considered not clinically meaningful. A 5-point change in NEI-VFQ-25 score is thought to represent a clinically meaningful change with respect to VA. [32] [33] [34] [35] The difference might have Copyright 2016 American Medical Association. All rights reserved.
been higher had we included the nonparticipants who had higher HbA 1c levels on entry and throughout the DCCT and more renal and neurological complications related to their diabetes. These were all factors associated with a decline in patient-reported visual function outcomes based on our analyses. Together with the tendency for more nonresponders to be in the conventional treatment group than the intensive treatment group (55.8% vs 44.2%, respectively), this suggests a selection bias to our cross-sectional analysis. This may have influenced our modest treatment group effect and resulted in an underestimation of the beneficial effect of intensive diabetes management on patient-reported visual function. Another explanation for the relatively high NEI-VFQ-25 scores in both the conventional and intensive treatment groups was the preservation of good VA in both groups (81.3% of participants with intensive treatment and 76.2% of participants with conventional treatment had VA ≥20/20 in the better eye), despite differences in the presence of severe retinopathy between the groups. Projecting forward, the 30% to 50% increases in severe eye disease and macular edema in the conventional treatment group are likely to progress over time, adversely affect VA, and thus more substantially affect the NEI-VFQ-25 score in the conventional treatment group. Supporting this premise, we reported the increase in ocular surgical procedures in the conventional treatment group compared with the intensive treatment group, which were principally complication-related surgical procedures largely performed to improve VA. 31 In the end, the success of these surgical procedures in restoring VA may also help in sustaining high patient-reported visual function. Preserving VA over time in patients with diabetes remains critical. Analysis of the NEI-VFQ-25 subscales demonstrates a consistent trend in the conventional treatment group: more difficulty with distance activities, such as driving, was reported by the conventional treatment group. Over time, visual impairment and limitations in driving in the aging population can induce feelings of depression and anxiety, a subscale also found to be statistically lower in the conventional treatment group compared with the intensive treatment group.
Not surprisingly, multivariate analysis demonstrated that other known diabetes-related outcomes, such as the presence of clinically significant renal or neurologic disease, and diabetes duration were independently correlated with patientreported visual function. It is these latter diabetes-related factors, reflecting longer duration of poor control in the conventional treatment group and affecting DQOL, and not hypoglycemia, that likely mitigate the modest association of low DQOL with NEI-VFQ-25 score.
A limitation of this study is the lack of baseline NEI-VFQ-25 score at DCCT entry. However, given that the DCCT was a well-designed randomized clinical trial and that retinopathy, VA, and all the other major risk factors were well balanced between the 2 treatment groups at baseline, we believe that the baseline NEI-VFQ-25 score should also be balanced between the 2 groups and therefore should not substantively bias our study conclusions. Lastly, the tool itself (NEI-VFQ-25) may limit the benefit of intensive treatment as it reflects the patient's impression from the viewpoint of the better eye, giving 2 chances to report adequate visual function.
Conclusions
In summary, our findings show that in the EDIC cohort patient-reported visual function remains high in both treatment groups, with only a modest benefit accruing to the intensive treatment group. This may reflect, in part, the relatively good VA in this cohort, the factor with greatest effect on patient-reported visual function outcomes from among all risk factors.
